Mike Grey

Venture Partner

Managing an early stage life science company requires vision, expertise, patience and commitment. Mike’s strong background in pharma and biotech company management enables him to bring a unique perspective to new deal opportunities and existing portfolio companies.

Mike has been a Venture Partner with Pappas Capital since January 2010 and served as a member of our Board of Advisors from 2004 to 2010. Mike currently serves as Executive Chair of Amplyx Pharmaceuticals, a Pappas Ventures V portfolio company, and Spruce Biosciences. He also serves as Executive Chair of Reneo Pharmaceuticals, a Pappas Ventures V portfolio company that he co-founded. In 2011, he spearheaded the founding of Lumena Pharmaceuticals, a Pappas Ventures IV portfolio company, and served as Chief Executive Officer until it was acquired by Shire plc in June 2014. Prior to Lumena, Mike was President and CEO of Auspex Pharmaceuticals, and President and CEO of SGX Pharmaceuticals (until its sale to Eli Lilly). Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma, from 1994 to 1998, and served as President and COO for Ansan during 1994. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President, Corporate Development and head of worldwide business development.

Mike serves as a director for BioMarin Pharmaceutical (NASDAQ: BMRN), Biothera Pharmaceutical, Horizon Pharma (NASDAQ: HZNP) and Mirati Therapeutics (NASDAQ: MRTX), a Pappas Ventures III portfolio company. He previously served on the boards of directors of Balance Therapeutics, a Pappas Ventures IV portfolio company, Selventa, a Pappas Ventures II portfolio company, Ziarco Pharma (acquired by Novartis), and three public companies: SGX Pharmaceuticals, IDM Pharma and Achillion Pharmaceuticals.

Education:

University of Nottingham, United Kingdom (BS in Chemistry)

“Whether as CEO, board member or advisor, there is great fulfillment in helping to grow companies that develop new drugs for important medical needs.”